The role of incretin-based therapies in the management of type 2 diabetes
Russell-Jones, D (2009) The role of incretin-based therapies in the management of type 2 diabetes Practical Diabetes International, 26 (5).
Full text not available from this repository.Abstract
In patients with type 2 diabetes mellitus (T2DM), goals for blood glucose and other cardiovascular risk factors, such as blood pressure and body weight, can be difficult to achieve. Recent clinical trials indicate that incretin-based therapies - dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 (GLP-1) agonists - help to achieve glycaemic goals and are generally well tolerated, with a low prevalence of hypoglycaemia. GLP-1 agonists also improve weight, blood pressure and markers of β-cell function. Addition of an incretin-based agent may be appropriate for selected patients with T2DM and unsatisfactory glycaemic control on conventional therapies. Copyright © 2009 John Wiley & Sons.
Item Type: | Article | ||||||
---|---|---|---|---|---|---|---|
Divisions : | Surrey research (other units) | ||||||
Authors : |
|
||||||
Date : | 27 November 2009 | ||||||
DOI : | 10.1002/pdi.1368 | ||||||
Depositing User : | Symplectic Elements | ||||||
Date Deposited : | 17 May 2017 09:05 | ||||||
Last Modified : | 24 Jan 2020 16:00 | ||||||
URI: | http://epubs.surrey.ac.uk/id/eprint/822233 |
Actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year